Home
Mabwell

Mabwell Market Share Analysis for May 2026

迈威生物是一家全产业链布局的创新型生物制药公司，始终秉承“让创新从梦想变成现实”的愿景，践行“探索生命，惠及健康”的使命，通过源头创新，为患者提供疗效更好、可及性更强的生物创新药，满足全球未被满足的临床需求。

Health > Biotechnology and Pharmaceuticals

Domainmabwell.com

Year Founded2017

Employees1001 - 5000

Annual Revenue$2M - $5M

Mabwell

Mabwell (including company regionals)

mabwell.com

See more website traffic and engagement information

Mabwell Revenue up to May 2026 is 2M - 5M

revenue generated by Mabwell top domains

Mabwell top domains revenue over 3 years

Revenue for Mabwell top domains

mabwell.com2M - 5M

See more with Sales Intelligence

Total visits to Mabwell's top domains

Understand Mabwell market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

mabwell.com6.2K

See more with Sales Intelligence

Avg. visit duration in Mabwell's top domains

Analyze Mabwell engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

mabwell.com00:00:46

See more with Sales Intelligence

Avg. pageviews on Mabwell's top domains

See how Mabwell keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

mabwell.com2.58

See more with Sales Intelligence

Mabwell top competitors by domain

Top similar sites in May 2026, ranked by their affinity

aditumbio.comCompany NameAditum BioEmployees51 - 200HQUnited States, California, OaklandAnnual revenue--Total visits2.8KN/A

Top technologies used by Mabwell

These are the website technologies, by industry, used by Mabwell top domains

Advertising (1)

PubMatic

Conversion & Analytics (1)

CNZZ

Email Services (1)

QQ Mail

Mobile (1)

Meta Viewport

More Technologies

2

See all

News & Signals from Mabwell

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMabwell (Shanghai) Bioscience Co., Ltd. identified as competitor of Pfizer Inc on Jun 19th '26.Mabwell's Nectin-4 ADC challenges Pfizer's Tivdak with 77% response rate in combination study.

NewsMabwell (Shanghai) Bioscience Co., Ltd. attended event 2026 ESMO Gynaecological Cancers Congress on Jun 17th '26.Mabwell presents clinical results of nectin-4-targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress.

NewsMabwell (Shanghai) Bioscience Co., Ltd. attended event 2026 ASCO Annual Meeting on May 21st '26.Mabwell announces latest clinical data on 9MW2821 to be presented at 2026 ASCO Annual Meeting as oral and poster presentations.